Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is
nveloped viruses are found across diverse viral families and cause some of the deadliest diseases known to man. Despite a spectrum of differences in their biology and pathogenesis, all enveloped viruses share two commonalities: a lipid bilayer envelope co-opted from host cells following viral egress, and the presence of surface-exposed viral glycoproteins for host cell recognition and entry. These viral glycoproteins, or 'spike' proteins, are exposed to the adaptive immune response and are the main targets of host antibodies, often being the only exposed antigen. Naturally, viruses have developed mechanisms to avoid such responses through rapid evolution of antibody-targeting epitopes, steric shielding of epitopes by glycan post-translational modifications, immune decoys such as soluble antigens that share viral spike epitopes, and immunosuppression to evade host recognition following cellular entry. In response to the viral arms race, antibodies have in turn developed many creative solutions to overcome viral evasion, including unique structural adaptations that allow them to more readily penetrate the viral armour and exploit sites of vulnerability.
The nature of the enveloped viral surface has major consequences for viral entry and, consequently, how the adaptive immune system responds. For enveloped viruses, entry hinges on the mechanics of the viral glycoprotein. Vital to the function of glycoproteins is their ability to fuse viral and host membranes together. Generally, this is achieved through a complex mechanism, where initial binding to a specific cellular host receptor usually results in drastic changes in the structure of the viral spike that enables transition to the post-fusion conformation. Successful triggering of post-fusion glycoprotein forms provides the energy necessary to fuse the viral and cellular membranes, thereby forming pores that allow the viral genomes to gain entry into the cytoplasm 1, 2 . Once entry is achieved, viral replication takes place using a variety of strategies, both in the cytoplasm and/or nucleus, but concludes in assembly and budding of new viral progeny at the host cell surface. For enveloped viruses, a neutralizing antibody (nAb) disrupting the viral lifecycle almost always involves binding to the viral glycoprotein, which can then disrupt entry by blocking one or more of the processes described above. Additionally, antibodies can also block viral egress by binding to glycoproteins on the infected cell surface, preventing viruses from budding. Thus, neutralization is achieved by preventing progeny from infecting a new cell, in a mechanism that is distinct from neutralization achieved by blocking entry (Fig. 1) . The pathogenesis of the three viruses that we describe here represent gradations of antigenic exposure to the adaptive immune system and also greatly influence the molecular nature of the antibodies formed in response to infection, which we will discuss at length later. Specific details regarding the lifecycle and pathogenesis of these viruses are summarized in Table 1 . While nAbs represent the overwhelming majority of our understanding of the antibody-based immune response to enveloped viruses, especially with respect to their structure, some non-neutralizing antibodies have also been shown to provide protection in vivo; however, this Review will predominantly focus on nAbs.
Due to the potency, specificity and tolerability of antibodies, they have become popular as therapeutics for viral disease and are also the intended outcome of most vaccines. It is therefore vital to understand not only where antibodies bind to viruses, but the molecular nature of the interaction. Structural biology has led the way in describing how antibodies interact with viral glycoproteins. While X-ray crystallography has long been the primary technique for solving high resolution structures, single particle electron microscopy (EM) has also recently become a powerful and increasingly used method for determining structures of viral antigen-antibody complexes, reaching resolutions comparable to X-ray crystallography. These data are critical for the structure-based design of the next generation of immunogens to elicit neutralizing and protective antibodies as well as for the selection and design of improved antibody therapeutics.
In this Review, we summarize recent advances in our understanding of neutralizing antibody responses to enveloped viruses, particularly from a structural perspective, with a focus on human immunodeficiency virus (HIV), influenza and filoviruses, for which there is a wealth of structural and immunological data. We first describe the overlapping and unique characteristics of each viral lifecycle, glycoprotein structure and pathogenesis. We highlight how structural biology has delineated the immunogenic landscape of these viruses and how antibodies have adapted to target these sites of vulnerability. We also discuss common and divergent themes among immune responses to these viruses and, importantly, how this information is being utilized to inform design of vaccines, therapeutics and diagnostics. Finally, we briefly comment on the role of antibodies in the recruitment of mediators of cellular immunity, the emerging role of Fc-variants, and how lessons learned can translate to other viruses and address future outbreaks.
nAbs and glycoprotein structures
A wide variety of immunoglobulins (Ig) are produced in humans, each with different roles in the immune response. The Ig gamma (IgG) form is by far the most extensively studied class of Ig, due to its extremely important role in immunotherapeutics as well as in viral immunity. Although there are very few structures of intact IgG that have been determined and subsequently published [3] [4] [5] [6] , hundreds of structures of antibody variable domains have been described in the literature at length, usually as fragment antigen binding (Fab) alone and in complex with cognate antigen 7, 8 . IgGs can be segregated into two identical Fab domains, which are responsible for binding and recognizing specific antigens, and a single fragment crystallizable (Fc) domain, which is responsible for communicating the presence of pathogens through binding to a limited set of cellular receptors, known as Fc gamma receptors (FcγRs) (Fig. 2) . Like a wrench thrown into the gears of a machine, antibodies are able to neutralize or protect against viruses by blocking one or more biological processes during viral entry or exit. The mechanism of neutralization depends largely on which epitope the antibody targets, and this subsequently determines which process is slowed or inhibited completely. For HIV, antibodies may block primary CD4 receptors (1) or secondary CCR5/CXCR4 co-receptor binding (2) . Filoviruses and influenza do not enter cells at the surface, but may be blocked by preventing attachment (3) or pinocytosis (4). For filoviruses, after endocytosis, antibodies must stay attached, survive acidification and, subsequently, prevent endosomal cleavage (5) or block endosomal receptor binding (6) . For influenza, receptor binding can be blocked at the cell surface (7) . In all cases, if receptor binding occurs, antibodies may directly block fusion through binding to fusion machinery. If viruses enter the cell, antibodies can potentially block egress of progeny virus (8) . Non-neutralizing pathways to antibody-based protection include tagging cells for destruction by effector cells before viruses have a chance to exit (9) (for example by antibody-dependent cellular cytotoxicity or by complement) or through agglutination of virions, which can then be destroyed by effector cells (10) . Flu, influenza; filov; filovirus.
The overwhelming majority of antibodies that provide sterilizing protection from infection target the viral spike. Therefore, the structure of the glycoprotein greatly influences how antibodies are selected, matured and specifically interfere with the mechanics of viral entry. Many enveloped glycoprotein structures have been solved, including those of the viruses discussed here, and have provided extensive insight into their mechanism of entry, as discussed in Fig. 3 . Such details have led to enveloped virus membrane fusion proteins being classified into three groups based on their structure and mechanism of entry 2 . For the purposes of this Review, we will focus on the type-I fusion glycoproteins, which compose the glycoproteins of HIV, influenza and filoviruses. However, while these three viruses are well-characterized examples, they do not represent the complete list of viruses that have contributed to our understanding of the antibody-based immune response to viruses containing type-I glycoproteins.
Type-I glycoproteins are expressed as single polypeptides that, after proteolytic cleavage, give rise to the pre-fusion, metastable viral spikes that are present on the surface of viruses. Type-I glycoproteins are composed of heterodimers arranged in a homotrimeric arrangement. Each protomer is identical and includes an ectodomain, consisting of an N-terminal portion; the receptor-binding domain (RBD) that houses the receptor binding site (RBS); and a largely C-terminal portion containing the fusion machinery, a transmembrane anchor, and often some type of internal C-terminal tail. Within the fusion machinery, a hydrophobic linear sequence of amino acids, known as the 'fusion peptide' or 'internal fusion loop' , is sequestered or partially buried, waiting to be released following receptor engagement. In each of the viruses discussed here, binding to specific host cell receptors is not sufficient to activate viral fusion. Rather, there are multiple steps required before glycoproteins become fusion competent. Once the fusion peptide is released, it is thought that it inserts itself into the host membrane and anchors the viral and host membranes together 2 . Helices within the fusion domain combine to form an elongated helix and thereby 'zip' into their post-fusion form, creating an extended coiled-coil intermediate. The extended intermediate eventually collapses into a 6-helical bundle, bringing the inserted N-terminal fusion-peptides and C-terminal transmembrane anchor regions together to create the glycoprotein's post-fusion form. This structural rearrangement provides the necessary energy to bring the viral and host membranes close together, forming a pore sufficient for the genetic material to enter into the cytoplasm. Pre-and post-fusion structures representing influenza 9, 10 , HIV (refs. [11] [12] [13] [14] ) and filoviruses 15, 16 have all been previously described, and were instrumental in detailing the processes described here.
Covering the surface of all glycoproteins are a variety of glycans, which are typically found to be more concentrated in the N-terminal The complex biology of HIV, influenza and filoviruses is difficult to categorize and each respective field has developed its own jargon to describe each virus. Here, we summarize the basic aspects of each viruses' biology, taxonomy and pathogenesis to provide a perspective on their commonalties and divergence in a variety of categories relevant to the antibody-based immune responses. This table is not meant to convey all aspects of the viruses, but rather to provide broad generalizations that allow some level of comparison.
RBD domains. The extent of coverage, type of glycan and attachment, and role in the viral life cycle, varies between viruses and is not completely understood. However, the most commonly attributed purposes of glycans are immune shielding [17] [18] [19] [20] and prevention of proteolysis 10 . For determination of some glycoprotein structures, glycans are trimmed back by glycosidases or occasionally deleted to facilitate crystallization, and therefore are often either not structurally characterized or are incompletely characterized. However, in other structures, these inherently flexible glycans can be explicitly resolved in both X-ray and cryo-EM structures, particularly when bound to antibodies 20 . Recent efforts to model glycans in silico and by mass spectrometry 21 , as well as by cryo-EM studies 22 , have also given a much greater understanding of the extent of glycosylation. Comparing structures of the type-I glycoproteins discussed here emphasizes the common structural themes among them (Fig. 3) . These structural motifs greatly influence the immune response and are reflected in the antibodies that are elicited, resulting in common themes among nAbs, which will be discussed in greater detail in the section titled 'Themes of antibody binding to enveloped glycoproteins' . It should be noted that, while HIV and filoviruses only have one glycoprotein on their surface, influzenza viruses have two, including hemagglutinin (HA) and neuraminidase, which aids viral egress. While nAbs against neuraminidase are significant and can provide protection, we will not discuss them in this Review.
themes of antibody binding to enveloped glycoproteins
Antibodies can provide sterilizing protection against viral pathogens, and finding antibodies that are potent against diverse strains of related viruses is highly desirable. Once such antibodies are identified and isolated, structural elucidation of their epitopes can reveal regions on the viral surface that can be targeted by vaccines and immunotherapeutics. One driver of antibody epitope mapping has been the utilization of EM to rapidly survey large numbers of antibodies through docking crystal structures into lower resolution cryo-EM maps [23] [24] [25] [26] [27] , and, recently, to map polyclonal antibody responses in sera 28, 29 . Structural studies have collectively revealed that antibodies utilize a plethora of strategies to recognize the wide range of surfaces and epitope locations on viral antigens, highlighting weak spots on the viral armour. In the following sub-sections, we outline some of these sites of vulnerability and point out common and divergent themes.
Receptor-binding sites and structural mimicry. All viruses utilize a host receptor in some capacity to gain entry into cells. Therefore, it is not surprising that the RBS is a major site of vulnerability for many viruses, since this region is an obligate component of the viral life cycle and is, therefore, relatively conserved, even under immune pressure ( Fig. 4a-c) . Viruses have evolved unique ways to escape this pressure. For example, HIV requires both a primary receptor (CD4), whose binding site is sterically difficult for antibodies to access 11, 12 , as well as a co-receptor (CCR5/CXCR4), whose binding site is sequestered and only formed and accessible after CD4 binds 30 . Nevertheless, many broadly neutralizing antibodies (bnAbs) have now been identified that target the CD4-binding site 31, 32 . Influenza virus' sialic acid binding site is easily accessed on the HA head 33 and is relatively well-conserved, although some mutational variability can be tolerated within this region 34, 35 , and RBS-adjacent regions can actually vary substantially 36, 37 . Efforts to engineer broader specificity into RBS-targeting antibodies has been met with difficulty, as RBDs occupy relatively small patches on the viral glycoprotein surface compared to the size of an antibody footprint 38 and, therefore, there are many places where the virus can escape neutralization by changing sequence in regions surrounding the RBS. Thus, strain specificity is more typical 39 , and true bnAbs against the RBS are rare [40] [41] [42] . The Ebolaviruses on the other hand require massive proteolytic remodelling for their RBS to become exposed within the late-endosomal compartment and, therefore, the RBS is hidden from the immune system on free virions [43] [44] [45] . However, conservation of the RBS on all filoviruses, and the differential exposure of the RBS on Marburgviruses in particular 46, 47 , has shown that panfiloviral antibodies are possible 24, 48 . Just as viruses have evolved complementary grooves on their protein surfaces for receptor binding, antibodies have also evolved into molecular mimics that can imitate these receptors to some extent. In such cases, binding can be quaternary in nature, involving loops that contain specific sequences or motifs similar to the actual receptor 30, 33, 38, 40, [49] [50] [51] [52] [53] [54] . This mimicry may involve one or more complementarity determining region (CDR) loop. The structure of an antibody is thus well-suited for performing receptor mimicry, and there are examples for each of the viruses discussed here (Fig. 4a-c) .
HIV relies on the interaction with its receptor, CD4, in a conserved binding pocket near the base of gp120 to achieve the structural changes required for interaction with its secondary receptors 30, 55 . Similar to IgG, CD4 is also composed of the Ig-fold; thus, antibodies are predisposed to recognize the CD4 epitope 56 , although they consist of twin Ig domains rather than one for CD4. The VRC01 class of antibodies target the CD4 binding site (Fig. 4a) and are typically very broadly reactive and potent 57, 58 . Although these antibodies mimic some aspects of CD4 binding to receptor 55 , they do not induce the large structural changes associated with receptor binding. Monoclonal (m)Ab b12 from long-term survivors, although less potent and broad, more closely emulates the CD4 receptor in that it does induce some structural changes, though not to the same extent as CD4 binding 30, 59 . Each influenza HA monomer has a binding pocket that contacts sialic acid moieties on the cell surface as its receptor prior to entry, and relies on this interaction for endocytosis. While most of the known bnAbs against influenza virus target the more conserved HA stalk, some antibodies that contact the HA head also have some breadth in their binding and neutralizing capacity 33, 38, 40, [51] [52] [53] . For example, the crystal structure of F045-092 (Fig. 4b) , as well as other mAbs, reveals that such antibodies likely block entry by mimicking the way sialic acid binds by inserting a CDRH3 loop into the RBS on the HA head 38 . On this and other antibodies, a dipeptide on CDRH3 contains an Asp residue that directly mimics the carboxyl on sialic acid 38, 53 , and a hydrophobic residue that binds in the same hydrophobic pocket as the acetamido moiety of sialic acid 33, 38, 42, 54 . Occasionally, CDR2 inserts into the binding site instead of CDRH3 52 . While the strength of the monovalent interaction is often low, the added avidity of an IgG that can span HAs on the surface can substantially boost affinity and activity 52 . Similarly 51 , many other antibodies also contact the HA RBS, but have larger footprints 38 that extend into less conserved regions adjacent to the RBS and are therefore more strainspecific and less broadly neutralizing 33, 51, 53 . A remarkable example of structural mimicry was recently demonstrated for filoviruses. Antibody MR78 (Fig. 4c) , which was isolated from a panel of Marburg virus human survivor mAbs with potent neutralizing activity that targets the RBS (ref. 24 ), was shown to bind directly to the Niemann Pick C1 (NPC1) binding site, blocking receptor binding 48 . The motif displayed by MR78 includes hydrophobic residues that closely mimic the loops inserted by NPC1 (ref. 49 ). Ebolaviruses have evolved a more structured glycan cap 15, [60] [61] [62] , in contrast to the one found on Marburg viruses 47 , that occupies the RBS on the viral surface prior to cleavage by host proteases. The Ebolavirus glycan cap, NPC1 and the MR78 CDR loops, all bind to GP in a similar fashion. This three-way type of mimicry demonstrates a unique way that the immune system has been able to take advantage of vulnerable sites on GP and mimic structures that Ebolaviruses have evolved to avoid antibody recognition 63 . (PDB 5I8H) . e, The HA FP also sits near the base of the HA stalk and, similarly, is contacted largely by the HC of MEDI8852 (PDB 5JW3). f, For ADI-15878 (PDB 6DZL), contacts with the HC are made across HR1 and the FP is mostly in contact with the LC. g, The HIV antibody 10E8 (Env PDB 5V7J and 10E8 PDB 5T85 fit into cryo-EM electron density for EMDB 3312) has evolved to partially contact portions of the viral lipid membrane. h, HA stalk antibodies typically have the broadest neutralizing paratopes and CR9114 (PDB 4FQI) contacts large portions of the extended HA2 alpha-helix with its HC. i, bnAb ADI-16061 (GP PDB 5JQ3 and Fab PDB 5HJ3 fit into negative-stain electron density for EMDB 8698) binds far below the base of GP, contacting conserved hydrophobic residues within HR2 and the MPER. j, The long-term exposure of the immune system to HIV allows for extensive SHM and antibody evolution, producing antibodies like PGT145 (PDB 5V8L), with an extended CDRH3 that is made rigid by a beta-hairpin structure with hydrophobic residues and sulfated tyrosines. This allows the antibody to reach deep into the apex pocket of Env. k, Ebolaviruses have two glycoproteins, the viral GP trimer and the sGP dimer, which is expressed in large abundance during infection and is thought to be a type of immune decoy. The first 296 amino acids of GP and sGP are shared and the protective antibody 13C6 binds to both GP (left, PDB 5KEL) and sGP (right, PDB 5KEN) near a highly conserved residue (W275).
Fusion peptide. Recent work has revealed the fusion peptide at the N-terminus of the membrane-proximal envelope glycoprotein as a common site of vulnerability [64] [65] [66] . This short, hydrophobic sequence is vital to the fusion process and must be liberated from its buried or partially sequestered location in the stalk or stem of glycoproteins to contact the host cell membrane. This makes it a difficult, but ideal, target for nAbs due to the necessary sequence conservation within a viral family. Structures of antibodies reactive with the fusion peptide have been shown for HIV (refs. [66] [67] [68] ) (Fig. 4d) , influenza 23, 64, 69, 70 ( Fig. 4e) and Ebola 65,71-73 viruses (Fig. 4f) . In each case, antibodies that engage the fusion peptide do so either directly or partially 23 , and are broadly reactive.
The glycoprotein stalk and membrane-proximal external region (MPER). The viral stalk or stem emerges from the transmembrane anchor of glycoproteins and contains the membrane fusion machinery. This domain is composed of the second of the two glycoproteins (HA2 for influenza virus, gp41 for HIV and GP2 for filoviruses) as well as the N-and C-terminal regions of the first membranedistal glycoprotein (HA1 for influenza virus, gp120 for HIV and GP1 for filoviruses). This central functional role also makes it an important site of vulnerability that is often highly conserved in sequence. With the exception of HIV-1 Env, access to this region was once thought to be difficult or impossible due to its proximity to the hydrophobic viral membrane and spike density 74, 75 . However, many potently neutralizing antibodies that can access this region have now been discovered for HIV (Fig. 4g ) and filoviruses 73, [76] [77] [78] [79] [80] [81] ( Fig. 4i) . The influenza stem is larger than in HIV and filoviruses, and is now appreciated as a more common site of vulnerability than once thought (Fig. 4h) , prompting the pursuit of potential vaccine candidates that focus on this region 80, [82] [83] [84] [85] [86] [87] [88] . The MPER connects the heptad repeat region 2 (HR2) to the transmembrane region and is involved in the fusion machinery. Remarkably, HR2-or MPER-directed mAbs for filoviruses contact epitopes nearly buried within the viral membrane (Fig. 4i) and, in HIV-1, such mAbs have additionally evolved to interact with lipids in the membrane 89, 90 or access transiently exposed hydrophobic residues 76 ( Fig. 4g) . There is not a well-defined MPER in influenza HA and consequently no antibodies to this specific region, as for the other viruses discussed here; however, the portion of HA that sits proximal to the membrane is referred to as the stem and does have spatially analogous regions to the MPER (ref. 91 ).
Virus-specific sites of vulnerability. In addition to the inherently common structural features that underlie all type-I viral GPs, there are many unique features that can also serve as hotspots for eliciting potent antibodies. Determination of the structures of antibodies in complex with HIV Env in particular, has uncovered some of the most unique examples 40, 92 . The duration of an HIV infection allows for a long-term arms race to commence among the increasingly diverse viral population and the host immune system 20, [93] [94] [95] [96] . This is aided, in part, by an extensive array of glycans on the surface of Env, which can help shield the underlying protein surface from immune surveillance. Strikingly though, this overabundance has given rise to antibodies that can bind directly and specifically to glycans that are highly conserved due to their high density, which protects them from secondary processing 20, 25, 26, [97] [98] [99] [100] . For example, antibody 2G12 exclusively recognizes immature high mannose glycans on HIV gp120 (refs. 27, 101, 102 ). While some glycan components of influenza and filoviral epitopes have been identified, they do not appear to play a role in antibody responses to the same extent as HIV-directed mAbs.
HIV Env also houses many important epitopes that are buried within the central core of the viral spike, only exposed transiently through 'conformational masking' 103 or after CD4 is bound 30 . At the apex of the HIV viral spike are several variable loops, including V1/V2 and V3, that can widely vary in sequence, but change position after CD4 binding and participate in co-receptor binding 11, 12, 30 . These hidden epitopes are still accessible by antibodies, often through non-classical methods of antibody binding. For example, broadly neutralizing antibodies PG9 and PGT145 (Fig. 4j) bind to the apex through very long CDRH3 loops (>30 residues) that can penetrate deep into recesses in the trimer apex. These Abs also bind asymmetrically where only a single Ab binds at the apex compared to most other HIV antibodies where three Fabs can be accommodated per trimer 98, 104 . However, some more recently identified antibodies can bind to the Env apex with shorter CDRs and with a stoichiometry of up to two Fabs per trimer 105, 106 . A common theme among such antibodies is the quaternary nature of their epitopes, requiring an intact trimeric spike and at least two protomers for binding, which is a mode of antibody binding that was not fully appreciated until the first structures of trimeric Env were determined 11, 12 . To achieve such complicated binding modes, these antibodies have often undergone extensive somatic hypermutation (SHM) that involves stabilizing mutations in framework regions, CDR loops that support the structure of the long inserting loops, such as CDRH3, in the paratope, and extended secondary structure within the CDR loops themselves. Conversely, some of the most potently neutralizing antibodies to influenza have far less SHM [107] [108] [109] [110] and typically much shorter CDRH3 loops, likely reflecting the much more acute nature of these infections and the possibility of first responder or 'SOS-like' antibodies in the human immune repertoire that evolved as a rapid defensive against infection 111, 112 . On Ebolaviruses, a structure referred to as the glycan cap, which covers the RBS, has been attributed to eliciting several neutralizing antibodies, despite its cleavage and removal following entry 62 . The glycan cap and portions of the core GP are also shared with a second GP product known as sGP, which is secreted abundantly during infection 113, 114 . Consequently, antibodies, such as 13C6, that react with the glycan cap are often cross-reactive to sGP [115] [116] [117] ( Fig. 4k) . Therefore, the mechanism behind how such antibodies neutralize Ebolaviruses is not well understood; Marburgviruses do not produce sGP or have a defined glycan cap, and instead leave their RBS exposed on virions 47 . Antibody allostery. Antibodies have also been shown to provide allosteric influence on glycoproteins, where binding in one location essentially alters a distal site. For example, HIV bnAb PGT151 binding to two sites on the HIV trimer induces asymmetry within the pliable Env structure, such that the third binding site on Env becomes inaccessible 76 . In a different but similar manner, antibodies have also been shown to exhibit cooperative binding, such as the binding of the Ebola virus (EBOV) antibodies FVM09 and m8C4, which do not offer effective neutralization or protection alone, but can potently neutralize EBOV in combination 118 . In this case, it is hypothesized that the binding of one alters the epitope of another, such that the epitope becomes more accessible.
Structures illuminate sites-of-vulnerability. The structures described here indicate that there are essentially no surfaces on viral glycoproteins that cannot be targeted by the adaptive immune response (Fig. 5 and Supplementary Table 1) . The diversity of antibody responses that occurs during infection demonstrates the extraordinary ability of the adaptive immune system to uniquely overcome viral obstacles. These studies provide valuable information that inform the development of next generation therapeutics and vaccines that can mirror these activities.
Vaccine, therapeutic and diagnostic development
Structural data that have been amassed for enveloped viral glycoproteins in the past few decades have informed a more fundamental understanding of the complex viral life cycle, but have also been used to directly and significantly advance efforts to generate and improve vaccines, therapeutics and diagnostics for these viruses. These efforts have been recently reviewed 119 ; therefore, we will briefly highlight the most significant advances in each of these areas.
Efforts to generate an effective HIV-1 vaccine have been slow and challenging. Traditional routes to vaccination do not produce the bnAbs that are necessary to protect against the hugely diverse range of viral strains that are circulating in different parts of the world [120] [121] [122] [123] . Failure has largely been fuelled by the complex biology of HIV Env, which is highly glycosylated, metastable, undergoes large structural changes during entry at the cell surface and can withstand large numbers of amino acid substitutions within the so-called 'hypervariable' regions 124 . To develop bnAbs, the adaptive response must overcome these obstacles through repeated exposure to a more diverse population of viruses, such as in long-term survivors 93, [125] [126] [127] . Being relatively rare, it took many years to identify and isolate such bnAbs in reasonable numbers, and less than a handful were available in the 1990s [128] [129] [130] [131] . Understanding how these mAbs recognize Env was further thwarted for many years by the lack of a stable and soluble form of Env that was suitable for structural studies. However, significant progress in antigen engineering resulted in the SOSIP antigen [132] [133] [134] [135] [136] that enabled the first antibody-Env structures to be solved by X-ray crystallography and cryo-EM 11, 12 . These early results helped to shape the next generation of Env subunit vaccine designs and have yielded two parallel efforts, exemplified the HIV and influenza fields. The first approach aims to present stable, idealized bnAb epitopes wherein sites of vulnerability on the viral glycoprotein are presented to the immune system in an idealized way. This typically is achieved in one of two ways: i) presentation of multiple epitopes on an intact, trimeric viral spike that is engineered for stability and limits exposure of known nonneutralizing epitopes [137] [138] [139] [140] [141] and ii) presentation of individual epitopes that are grafted onto protein scaffolds to immune-focus the antibody response to a particular site of vulnerability. Both of these approaches have advantages and disadvantages 142 . The epitopefocused approach has shown success as a proof-of-concept study with respiratory syncytial virus 142 and has since been expanded to show success in eliciting desired antibodies for HIV [143] [144] [145] , but has yet to show clinical success. However, epitope-focused vaccine designs have thus far not induced bnAbs [146] [147] [148] . Activity against the more complex and quaternary epitopes found on the intact, trimeric viral antigens can be lost or produce obstacles for antibodies elicited by monomeric designs. For HIV, more stabilized and engineered versions of a 'native-like' trimer indeed induced stronger neutralizing antibodies titers 149-151, but the responses generally lack breadth, only inducing antibodies that target the autologous immunogen. For influenza, the most broadly potent antibodies have been consistently mapped to the HA stalk. Therefore, an epitope-focused approach has been much more successful, where only the HA stalk is presented to the immune system 84, 87, 88, [152] [153] [154] [155] [156] or is presented in a chimaeric form with different HA heads to focus the immune system on the conserved stem region 152, 153, 156 . In these cases, neutralizing responses can be relatively high and contain a level of breadth. One possible explanation is that the HA stalk has a larger degree of sequence conservation across the viral landscape than HIV Env, and less glycosylation.
The second approach to vaccines is to design immunogens that can stimulate specific precursor B-cells that can evolve into bnAbs. Thus, these immunogens target the non-somatic germline genes that first recombine to form the B-cell receptor, and aim to emulate the early stages of infection to initiate an immune response that has the potential to mature to breadth and potency over time [143] [144] [145] 149, 157, 158 . This approach has arisen from analysing structures of known bnAbs and engineering immunogens to bind germline versions of these bnAbs. Thus, vaccination occurs in stages, by priming bnAb precursors and then 'guiding' these populations through subsequent vaccinations with immunogens that progressively drive somatic hypermutation toward bnAbs. The most advanced demonstration of these efforts has been shown by Schief and colleagues who used state-of-the-art animal models and analytics, such as next generation sequencing, to study immune responses in great detail 144, [159] [160] [161] . The germline-targeting approach has two major obstacles. First, not all individuals necessarily make a high frequency, or any at all, of the naïve B-cell populations to be targeted 162, 163 . Encouragingly though, some germline bnAb precursors have been found in naïve humans at low but sufficient frequency to initiate a response 144, 164, 165 . Indeed, as more bnAbs are found against particular epitopes, the frequency of the particular germlines in the naïve population can be taken into account in germline-targeting approaches. Additionally, longitudinal studies of the sequences and structures of bnAb evolution can provide clues as to how to better design immunogens that shepherd bnAb responses [166] [167] [168] [169] [170] [171] . The second hurdle of this approach is that targeting human germline genes is difficult to test in animal models. Here, humanized and knock-in mice have provided a valuable tool for at least providing proof-of-concept for this approach [172] [173] [174] . The B-cell origins of broadly neutralizing mAbs tend to be restricted to particular germline sequences. For example, the CD4 binding site bnAbs of HIV, and the stem-directed bnAbs of influenza, are often constrained to particular germline genes, namely V H 1-2/V H 1-46 (refs. 32,167,175 ) and V H 1-69 (ref. 108 ), respectively. Interestingly, broadly potent V H 1-69-derived nAbs are also found against a variety of other viral epitopes, including those found on Ebolaviruses 73, 79, 115, 116 and HIV-1 (refs. 32, 167, 176, 177 ). This commonality does not have an obvious underlying reason other than the CDRH2 of V H 1-69 antibodies has a hydrophobic tip that can insert into hydrophobic surfaces in viral antigens, particularly fusion domains 23, 81, 108, 109 . The prevalence of V H 1-69 does suggest a possible conserved immunological approach to targeting enveloped pathogens, which have evolved alongside humans for millennia 111, 112 . Conversely, immune responses are often very diverse, particularly within a single patient, as observed in those infected by filoviruses 24, 115, 116 . In these cases, SHM tends to be low, and the polyclonal response may be more vital to overcoming more acute filoviral or seasonal influenza infections with no or limited antigenic variability. Effective responses to the hypervariable HIV reflect the longer exposure to the virus, where SHM is high within one or more predominant clonal lineages of antibodies. Influenza virus infection is acute but can occur in an individual multiple times over a lifetime through seasonal variants, and antibody responses to seasonal strains are a mixture of recall and de novo antibody responses 85 . Stem antibodies have greater promise for neutralization breadth due to conservation in the stem of HA, but are restricted to only a few antibody lineages, although not to V H 1-69. These lessons from natural infection provide important clues as to how to approach vaccine and therapeutic design, and can be tuned to the particular virus.
Vaccine and therapeutic development for filoviruses has experienced a surge in research due to a recent and unprecedented outbreak in Western Africa from 2013-2016 (ref. 178 ). Outbreaks of filovirus infection are relatively rare and most often isolated to sub-Sahara Africa; therefore, there was little information on the antibody-based response to exposure. Prior to the 2013 outbreak, there was evidence to suggest that neutralizing immune responses to infection were rare and that immunotherapy may not be possible or that vaccination may be difficult 179 . However, several studies that appeared during the last major outbreak showed that humanized mouse-derived mAbs, when used in combination, could provide protection. Two of these therapies, ZMab (ref. 180 ) and MB-003 (ref. 181 ), were recombined into the tri-mAb cocktail ZMapp (ref. 182 ), which demonstrated complete protection in non-human primates at late stages of infection 183 . Conducting trials of ZMapp were met with some difficulties due to the waning outbreak, and demonstration of protective efficacy in humans could not be fully substantiated 184 . One vaccine trial, however, did show great promise 185 , and there is evidence for long-term sustained protection in survivors of natural infection 186 . A new outbreak of Ebola virus in 2018 in the Democratic Republic of the Congo has seen the use of ZMapp as well as another tri-mAb cocktail from Regeneron (ref. 187 ) and the single antibody mAb114 (ref. 188 ), and all three of these treatments are being evaluated in clinical trials in an effort to produce a treatment for Ebola virus infection that will be approved by the United States Federal Drug Agency (FDA).
Many new anti-Ebola Abs have been recently descri bed 24, 65, 71, 79, 115, 118 , including 26 new structures of antibodies and GP complexes that delineated major sites of vulnerability, including the IFL, glycan cap, base, head and HR2 region of GP (ref. 189 ). These studies demonstrate the polyclonal diversity of anti-filovirus antibodies. Additionally, several human-derived antibodies have been isolated that show broad cross-reactivity across Ebolaviruses or Marburgviruses, and are actively being evaluated for use as immunotherapies. As for HIV and influenza, these bnAbs will likely be more restricted to particular germlines or sets of germlines. By understanding the mechanism of broadly neutralizing antibodies, it is hoped that this information will lead to pan-filoviral therapies that could replace the single species-focused ZMapp, which would not be effective against the many other filoviral species that are pathogenic to humans.
Humanized mice offer an alternative platform to study antibody reponses than human survivors of pandemic and epidemic viral infection. A recent study in which VelocImmune mice 190 were vaccinated with either DNA-encoded or -soluble Ebola virus GP (Makona variant) demonstrated that fully human IgGs could be produced in mice, which bind to common sites of vulnerability on filoviruses that are targeted by the human immune system. Remarkably, these antibodies provide comparable protection to other therapies, including the ability to engage human Fcγ receptors, providing some level of protection through non-neutralizing means, similar to c13C6 from ZMapp (ref. 183 ). This study shows that, in principal, these mice can be vaccinated against any pathogen to produce antibodies that may offer protection in humans, but on a much faster timeline, making them an attractive option to learn how to combat other emerging infectious diseases.
Future perspectives
The plethora of structural information that has been generated in the past decade has opened many doors for understanding how the adaptive immune system recognizes and neutralizes enveloped and other viruses, resulting in exciting new vaccine and antibody therapeutic development opportunities. One trait that is shared amongst nearly all neutralizing antibodies examined thus far, and reviewed here, is the restricted range of angles (90°) of approach to viral spikes (with respect to the viral membrane). The majority of neutralizing antibodies approach at a steeper angle nearly perpendicular to the membrane (PG9, PGT145, CAP256, CH01-4, VRC38, C05, 13C6), while others approach at a nearly parallel angle to the membrane (VRC01, FI6, CR8781, 10E8, KZ52, 4G7, ADI-16061). These allowable angles then likely reflect the window in which naïve B-cell receptors can successfully engage the viral membranebound antigen for the prolonged periods required for activation, with the viral membrane providing some constraint and limiting angles beyond 90°. Upward angles are unfavourable for soluble IgGs as the membrane provides a steric constraint for approaching glycoproteins to bind 141 , although strain-specific neutralizing antibodies that approach glycoproteins at such an angle are not unheard of for filoviruses 61, 182, 189 . Additionally, the density of viral spikes on the surface of a virus can facilitate bivalent binding, which is possible for GP (ref. 191 ) and HA (refs. 38, 51, 52, 192 ), but perhaps less so for HIV where the spike density can be quite low 75, [193] [194] [195] . In this case, engineering bivalent binding within a single antigen may be an effective approach to overcoming lower monovalent binding affinity to broadly reactive epitopes 195, 196 .
The examples described here demonstrate the near infinite capacity of the adaptive immune system to evolve in response to diverse antigenic insults that humans and animals encounter. The diverse epitopes targeted by acute Ebolavirus infection 115 demonstrate how a polyclonal antibody response with low SHM can be very effective, while the incredible breadth and potency of monoclonal bnAbs isolated from chronically infected HIV patients reveal the extremes of SHM that antibodies can accommodate to overcome huge antigenic diversity [197] [198] [199] [200] . Despite this adaptive potential, the immune system still has a difficult time keeping pace with antigenically variable viruses, such as influenza and HIV, that have high mutation rates 94 . Superficially, one would expect influenza to be an easier target for antibodies, particularly with yearly boosts through seasonal infection or vaccination. Yet, bnAbs are rare and typically do not persist, meaning the worldwide human population is under constant threat of a new influenza pandemic. On the other hand, Ebolaviruses may well be a relatively easy target for the adaptive immune system, but its spectacularly rapid pathogenesis normally results in mortality before effective antibodies can be made. We sometimes take for granted the wonderful arsenal of vaccines that have already been developed, largely by empirical methods, which result in lasting immunity with impressive potency. Of course, most of the viruses at which these vaccines are aimed have little variability. Ironically, we have a relatively limited understanding of the sequence and molecular basis of antibody responses to historical vaccines and a much greater understanding of the antibody responses to pathogens that continue to outpace current vaccines. Even then, the monoclonal antibodies that have been successfully isolated and structurally characterized are almost certainly under-representative of the true diversity of immune responses. Thus, the pursuit of new antibodies, and therefore new pathways to bnAbs, remains highly valuable. Understanding polyclonal responses to large antigenic surfaces during infection/vaccination 29 also holds future promise for improving vaccines that increase and decrease on-and off-target responses, respectively.
As noted above, a structure-based vaccine design for HIV has already generated some encouraging results in animal models that demonstrate it is possible to drive the path of antibody evolution towards a neutralizing, but not broadly neutralizing, response by vaccination with candidate immunogens 144, 145, 159, 164, 165, 173 . Here, vaccine design increasingly benefits from a deeper understanding of the basic biological processes that happen in B-cell germinal centers 165, 201, 202 , as well as antigen display and uptake. There is also renewed interest in the role of the innate immune pathways in antibody-based protection, as well as the role of nonneutralizing antibodies 118, [203] [204] [205] [206] . Fc-mediated protection has been shown to play at least some part in providing protection from all viruses discussed here. Even neutralizing antibodies have often been found to rely on some level of Fc-mediated function to realize their full potency 207, 208 . While there is a basic understanding of the antibody-based innate immune response [209] [210] [211] [212] , there is still much to be learned about the subtleties of the molecular nature of effector cell activation. Future studies to address the role of Fc-mediated protection in individuals that effectively control HIV replication, as well as in those that survive filovirus infection, will enhance vaccine and therapeutic research. A more detailed molecular understanding of the immune activation complex, and what type of antibodyantigen interaction results in a potent innate immune response, could help to improve antibody therapeutic selection and engineering. Further, these types of studies may provide information that will guide antibody designs that can specifically recruit effector cell subsets and immune responses, such as natural killer cells and antibody-dependent cellular cytotoxicity, which have shown great promise in augmenting antibody neutralization 213 . Based on the incredible advances described above, it is conceivable that, in the not so distant future, we will be able to rationally design vaccines that elicit antibodies with epitope specificity and broad antigen reactivity. An exciting new challenge will be the design of vaccines that also elicit antibodies that can potently and specifically recruit desired effector functions. Integrating lessons from different viruses, including those described here, will continue to provide insights to arm researchers in their quest to vanquish the most formidable of pathogens.
